Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide found in the gut, lungs and brain. A synthetic version, aviptadil, has been tested in clinical trials. VIP is not FDA approved for any use.
Also known as: Vasoactive intestinal peptide, Aviptadil.
Powder vials are usually labeled 5 mg.
Water and syringe-unit charts by vial size: 5 mg
Here is the math for a 5 mg vial mixed with 2 mL of bacteriostatic water, drawing 50 mcg with a U-100 insulin syringe (1 mL = 100 units).
5 mg ÷ 2 mL = 2.5 mg/mL50 mcg ÷ 2.5 mg/mL = 0.02 mL0.02 mL × 100 = 2 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 25 mcg | 0.01 mL | 1 units |
| 50 mcg | 0.02 mL | 2 units |
| 100 mcg | 0.04 mL | 4 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
In an open phase 2 study (Prasse 2010), 20 people with active sarcoidosis inhaled nebulized VIP for 4 weeks. It was well tolerated and lowered an inflammatory signal (TNF-alpha) in lung fluid; there was no placebo group.
In the TESICO trial (Lancet Respir Med 2023), intravenous aviptadil was tested against placebo in hospitalized adults with COVID-19 respiratory failure. Evidence for VIP injected under the skin or used as a nasal spray outside trials is limited.
We could not open a primary human source with a half-life for VIP by the routes people use outside hospitals, so we do not list one here.